Literature DB >> 26935538

Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth.

M M Morrison, M M Williams, D B Vaught, D Hicks, J Lim, C McKernan, L Aurisicchio, G Ciliberto, C Simion, C Sweeney, R S Cook.   

Abstract

Entities:  

Year:  2016        PMID： 26935538     DOI： 10.1038/onc.2015.418

Source DB:  PubMed          Journal:  Oncogene        ISSN： 0950-9232            Impact factor:   9.867


× No keyword cloud information.
  4 in total

1.  MED23 in endocrinotherapy for breast cancer.

Authors:  Benrui Lin; Lan Zhang; Dinuo Li; Hongzhi Sun
Journal:  Oncol Lett       Date:  2017-04-13       Impact factor: 2.967

2.  Metastatic urothelial carcinoma harboring ERBB2/3 mutations dramatically respond to chemotherapy plus anti-PD-1 antibody: A case report.

Authors:  Fei-Fei Yan; Qi Jiang; Bin Ru; Xiao-Jie Fei; Jian Ruan; Xiao-Chen Zhang
Journal:  World J Clin Cases       Date:  2022-03-16       Impact factor: 1.337

3.  Integrated driver mutations profile of chinese gastrointestinal-natural killer/T-cell lymphoma.

Authors:  Shanshan Li; Tingzhi Liu; Hailing Liu; Xiaohui Zhai; Taiyuan Cao; Hongen Yu; Wanjia Hong; Xiaoru Lin; Ming Li; Yan Huang; Jian Xiao
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

4.  In silico analysis of differentially expressed genesets in metastatic breast cancer identifies potential prognostic biomarkers.

Authors:  Jongchan Kim
Journal:  World J Surg Oncol       Date:  2021-06-25       Impact factor: 2.754
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.